Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int Forum Allergy Rhinol ; 14(3): 716-719, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37506398

ABSTRACT

KEY POINTS: Nasal packing type was not associated with postoperative cerebrospinal fluid leaks Nondissolvable packing conferred an increased risk for postoperative sinonasal infections Nasal packing type did not influence short- and long-term quality-of-life scores.


Subject(s)
Plastic Surgery Procedures , Humans , Cerebrospinal Fluid Leak/surgery , Retrospective Studies , Skull Base/surgery , Endoscopy/adverse effects , Postoperative Complications/etiology , Quality of Life
2.
Nat Med ; 25(6): 1022, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30996326

ABSTRACT

In the version of this article originally published, the graph in Extended Data Fig. 2c was a duplication of Extended Data Fig. 2b. The correct version of Extended Data Fig. 2c is now available online.

3.
Nat Med ; 25(3): 462-469, 2019 03.
Article in English | MEDLINE | ID: mdl-30742119

ABSTRACT

Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where <10% of patients show long-term responses. To understand the molecular determinants of immunotherapeutic response in GBM, we longitudinally profiled 66 patients, including 17 long-term responders, during standard therapy and after treatment with PD-1 inhibitors (nivolumab or pembrolizumab). Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations associated with immunosuppressive expression signatures in non-responders, and an enrichment of MAPK pathway alterations (PTPN11, BRAF) in responders. Responsive tumors were also associated with branched patterns of evolution from the elimination of neoepitopes as well as with differences in T cell clonal diversity and tumor microenvironment profiles. Our study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor's clonal evolution during treatment.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Brain Neoplasms/drug therapy , Glioblastoma/drug therapy , Nivolumab/therapeutic use , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Adult , Aged , Brain Neoplasms/genetics , Brain Neoplasms/immunology , Female , Gene Expression Profiling , Genomics , Glioblastoma/genetics , Glioblastoma/immunology , Humans , Immune Tolerance/genetics , Immune Tolerance/immunology , Longitudinal Studies , Male , Middle Aged , Mutation , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/immunology , Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 11/immunology , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/immunology , T-Lymphocytes/immunology , Treatment Outcome , Tumor Microenvironment/genetics , Tumor Microenvironment/immunology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...